Display options
Cite
Poremba C, Hero B, Heine B, et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol. 2000;35(6):651-5doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i.
Poremba, C., Hero, B., Heine, B., Scheel, C., Schaefer, K. L., Christiansen, H., Berthold, F., Kneif, S., Stein, H., Juergens, H., Boecker, W., & Dockhorn-Dworniczak, B. (2000). Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Medical and pediatric oncology, 35(6), 651-5. https://doi.org/10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i
Poremba, C, et al. "Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas." Medical and pediatric oncology vol. 35,6 (2000): 651-5. doi: https://doi.org/10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i
Poremba C, Hero B, Heine B, Scheel C, Schaefer KL, Christiansen H, Berthold F, Kneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol. 2000 Dec;35(6):651-5. doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i. PMID: 11107139.
Copy Download .nbib Format: NLM
Share it on

Med Pediatr Oncol. 2000 Dec;35(6):651-5. doi: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i.

Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas.

Medical and pediatric oncology

C Poremba, B Hero, B Heine, C Scheel, K L Schaefer, H Christiansen, F Berthold, S Kneif, H Stein, H Juergens, W Boecker, B Dockhorn-Dworniczak

Affiliations

  1. Gerhard-Domagk-Institute of Pathology, Westfälische Wilhelms-University, Münster, Germany. [email protected]

PMID: 11107139 DOI: 10.1002/1096-911x(20001201)35:6<651::aid-mpo36>3.0.co;2-i

Abstract

BACKGROUND: As traditional parameters do not ensure completely accurate prognostic grouping in neuroblastoma (NB), new molecular markers are needed for assessing the individual patient's prognosis more precisely.

PROCEDURE, RESULTS, AND CONCLUSIONS: Based on 133 NB, we show that telomerase activity (TA) is a powerful, independent prognostic marker for all stages and is capable of differentiating between good and poor outcome in putative 'favorable' clinical or biological subgroups of NB patients. Analysis of gene and protein expression of telomerase subunits suggests that the presence or absence of TA in NB is strongly correlated with expression levels of both the catalytic subunit hTERT and the internal RNA component (hTR).

Copyright 2000 Wiley-Liss, Inc.

Substances

MeSH terms

Publication Types